Retatrutide is an investigational drug that is considered a tripe agonist, meaning it targets glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon hormone receptors. It has already been extensively studied throughout the TRIUMPH Phase 3 global registration clinical development program across several indications. As a once-weekly injection, it possesses great potential to be a new treatment option for a variety of conditions, including weight loss (1).
Retatrutide is a novel triple receptor agonist, targeting GIP, GLP-1, and glucagon receptors. These therapeutic targets have proven to be efficacious in other drugs such as tirzepatide, which is a GIP and GLP-1 receptor agonist. The triple action of retatrutide may therefore provide similar, if not greater effects (2).
Animal studies have shown that retatrutide can delay gastric emptying, decrease food intake, and induce weight loss to a greater degree than other incretin-based treatments. Phase I and II studies in humans support these findings, demonstrating dose-dependent reductions in weight, hemoglobin A1c (HbA1c) levels, and other improvements (3).
There several studies evaluating retatrutide included in the Phase 3 global registrational clinical development program TRIUMPH. In this program, retatrutide is being evaluated for the treatment of obesity and overweight as well as in conditions related to weight such as sleep apnea and knee osteoarthritis.
The most notable results so far come from the TRIUMPH-4 trial that assessed the safety and efficacy of retatrutide in adults that are overweight or obese with knee osteoarthritis and without diabetes. After a period of 68 weeks, retatrutide induced weight loss at an average of 28.7%. Additionally, pain was reduced by 4.5 points in the context of knee osteoarthritis.
In addition, retatrutide also decreased known markers of cardiovascular risks such as cholesterol, triglycerides, and blood pressure (1).
The evidence coming out of the TRIUMPH-4 trial is very promising considering this is a large and well-controlled study. Thus, individuals seeking retatrutide treatment can expect a fairly robust safety and efficacy profile when used for weight loss. Additionally, its mechanism is well-validated and is common across several other weight loss drugs.
Retatrutide is not yet approved by the US Food And Drug Administration (FDA), however, its strong safety and efficacy profile indicate that approval may be on the horizon. Currently, the drug is only available via clinical trials. An approval by FDA would indicate the drug has a well-established safety and efficacy profile that meets the agency’s stringent standards. The quality of the product would also be regulated and overseen by the FDA.
The findings from the TRIUMPH-4 trial show adverse events that are consistent with other incretin drugs. Most commonly experienced side effects include nausea, constipation, vomiting, decreased appetite, and dysesthesia (1).
Retatrutide shows immense promise in the realm of weight loss and beyond. Patients can likely expect an approval by FDA in the coming years, offering a new and robust treatment option for those struggling with excess weight.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
Advances in metabolic therapies highlight how powerful targeted treatments can be for weight loss and overall health. At Weight Loss & Vitality, we integrate these principles into our medical weight loss program, focusing on hormones, metabolism, and individualized care plans.
References
